Research Topics
| Daniel G HallerSummaryAffiliation: University of Pennsylvania Country: USA Publications
| Collaborators
|
Detail Information
Publications
Safety of oxaliplatin in the treatment of colorectal cancerD G Haller
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
Oncology (Williston Park) 14:15-20. 2000..Cumulative neurotoxicity is the dose-limiting toxicity associated with oxaliplatin treatment. This toxicity appears reversible with discontinuation of the drug and typically occurs well after the onset of tumor response...- Update on chemotherapy for advanced colorectal cancerD G Haller
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
Oncology (Williston Park) 15:11-5. 2001.... - Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodesAdam C Berger
Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
J Clin Oncol 23:8706-12. 2005..CONCLUSION: After curative resection for colorectal cancer, the LNR is an important prognostic factor and should be used in stratification schemes for future clinical trials investigating adjuvant treatments... - Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomasWeijing Sun
Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA, 19104 4283, USA
Cancer Chemother Pharmacol 67:621-7. 2011..Epirubicin, cisplatin, and irinotecan are active cytotoxic chemotherapy agents in UGI cancers... 
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinomaWeijing Sun
Abramson Cancer Center, Department of Medicine, Hematology Oncology Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Cancer 117:3187-92. 2011..This phase 2 study was designed to determine the efficacy and toxicity of the combination of bevacizumab, capecitabine, and oxaliplatin in patients with advanced unresectable and untransplantable HCC...- Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller
Abramson Cancer Center at the University of Pennsylvania, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19014 4283, USA
J Clin Oncol 26:4544-50. 2008..IROX improves efficacy compared with irinotecan alone, providing an additional option in the postadjuvant or second-line treatment setting for patients who experience treatment failure with single-agent fluoropyrimidine therapy... - Potential regional differences for the tolerability profiles of fluoropyrimidinesDaniel G Haller
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
J Clin Oncol 26:2118-23. 2008.... - Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancerUrsina R Teitelbaum
Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
Nat Rev Clin Oncol 6:250-1. 2009..This paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens... - Adjuvant therapy of colon cancerWeijing Sun
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
Semin Oncol 32:95-102. 2005..Novel molecular and biologic-oriented agents are being studied. Further analysis and definition of prognostic and predictive markers may allow future adjuvant therapy to be individualized... - Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089Daniel G Haller
University of Pennsylvania, Philadelphia, PA, USA
J Clin Oncol 23:8671-8. 2005..Intergroup (INT) 0089 assessed the relative contributions of leucovorin and levamisole in such patients... - Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flowJames P Stevenson
University of Pennsylvania, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA
J Clin Oncol 21:4428-38. 2003..The present study investigated escalating doses of CA4P administered intravenously to patients with advanced cancer... 
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancerM L Veronese
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA 19104, USA
Br J Cancer 92:1846-9. 2005..The combination of this standard chemotherapy regimen with gefitinib is associated with excessive toxicity, suggesting an interaction at a pharmacokinetic or pharmacodynamic level...- Chemotherapy for advanced pancreatic cancerDaniel G Haller
Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
Int J Radiat Oncol Biol Phys 56:16-23. 2003..Gemcitabine has thus become the de facto standard of care for advanced pancreatic cancer, and current efforts are directed toward finding strategies that can capitalize on and extend these clinical benefits... - Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancersDaniel G Haller
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
Semin Oncol 31:10-6. 2004..This review will examine recent clinical data on the use of platinum-based chemotherapies for the treatment of these gastrointestinal cancers... - Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancerDaniel G Haller
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
J Clin Oncol 29:1465-71. 2011..This multicenter, randomized trial compared capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil (FU) and folinic acid (FA) as adjuvant therapy for patients with stage III colon cancer... - Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinomaDrew Moghanaki
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
JOP 12:438-44. 2011..Pancreas cancer can potentially be cured by resection, but the role of adjuvant chemotherapy and/or chemoradiation has been controversial... - Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignanciesJoshua H Bilenker
Abramson Family Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
Cancer Chemother Pharmacol 53:357-60. 2004..The combination shows evidence of antitumor activity in a pretreated population... - Resection of the primary colorectal cancer is not necessary in nonobstructed patients with metastatic diseaseNevena Damjanov
University of Pennsylvania, Abramson Cancer Center at Penn Presbyterian Medical Center, 51 North 39th Street, Philadelphia, PA 19104, USA
Oncologist 14:963-9. 2009.... - A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancerWeijing Sun
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Cancer 110:2768-74. 2007..The current study was conducted to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of the combination... - Future directions with angiogenesis inhibitors in colorectal cancerJoshua H Bilenker
University of Pennsylvania Cancer Center, 3400 Spruce St, Philadelphia, PA 19104, USA
Clin Colorectal Cancer 4:S86-93. 2004..A better understanding of the determinants of response to antiangiogenic agents and their mechanisms of action, especially in combination with cytotoxic drugs, is crucial to future drug development... - Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancerM L Veronese
Abramson Cancer Center, University of Pennsylvania, 51 N 39th St, MAB-103, Philadelphia, PA 19104, USA
Eur J Cancer 40:508-14. 2004..Doses recommended for further study on this schedule are irinotecan 310 mg/m(2) and UFT 300 mg/m(2)/day, with LV 60 mg/day... - Adjuvant therapy for colon cancerWeijing Sun
Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
Curr Oncol Rep 7:181-5. 2005..The application of pharmacogenetics and pharmacogenomics in adjuvant therapy for colorectal cancer will help to distinguish those patients with risk factors and to guide individualized therapy... - Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281Weijing Sun
University of Pennsylvania, Philadelphia, PA 19104 4283, USA
J Clin Oncol 23:4897-904. 2005..Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of chemotherapy for symptomatic patients with progressive disease is uncertain... - Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative GroupsPETER J O'DWYER
Coalition of Cancer Cooperative Groups, Philadelphia, PA, USA
J Clin Oncol 25:2313-21. 2007..The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy... - Improved patient and regimen selection in locally advanced rectal cancer: who, how, and what next?Jared Weiss
Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, 19104, USA
Clin Colorectal Cancer 8:194-9. 2009..Given the success of NCRT in improving local control, distant metastasis now predominates as the cause of treatment failure, and larger gains will likely be made from improvements in adjuvant chemotherapy... - Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 daysWeijing Sun
Abrahmson Family Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Clin Cancer Res 9:5221-7. 2003..2 +/- 4.5 h, respectively. BMS-184476 60 at mg/m(2) with cisplatin at 75 mg/m(2) with appropriate supportive therapy is the dose recommended for further evaluation... - A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancerNeil E Martin
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Clin Cancer Res 10:5447-54. 2004..CONCLUSIONS: The combination of L-778,123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer. Radiosensitization of a patient-derived pancreatic cancer cell line was observed... - Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resectionNatalie E Joseph
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Ann Surg Oncol 10:213-8. 2003..Most patients are understaged. Underestimating nodal stage may influence decisions regarding adjuvant therapy, as well as overall prognosis... - Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancerC M Dolinsky
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
J Surg Oncol 96:207-12. 2007..Preoperative chemoradiotherapy for locally advanced rectal cancer is now considered "standard of care." However, the optimal time interval for resection after neoadjuvant therapy is unknown... - Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancerJ P Stevenson
Developmental Therapeutics Program, University of Pennsylvania, Philadelphia, USA
J Clin Oncol 19:4081-7. 2001..Functional polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene result in intracellular redistribution of folate derivatives, which may affect raltitrexed-associated cytotoxicity... - Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/CanceP J O'Dwyer
University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
J Clin Oncol 19:2413-21. 2001..To investigate mechanism-directed regimens in maximizing the efficacy of fluorouracil (5-FU) in advanced colorected cancer... - Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancerD G Haller
University of Pennsylvania Cancer Center, Philadelphia 19104-4204, USA
Semin Oncol 28:25-30. 2001..Completed and ongoing trials may support its use as monotherapy in stage II colon cancer or in combination with chemotherapy in stage III colon cancer and stage II/III rectal cancer... - Postoperative radiation therapy for rectal cancer combined with UFT/leucovorinD I Rosenthal
Department of Radiation Oncology, University of Pennsylvania Cancer Center, Philadelphia, USA
Oncology (Williston Park) 14:59-62. 2000..A combination of postoperative adjuvant UFT plus leucovorin concurrent with radiation therapy should be feasible, and the design of an ongoing phase I trial is presented... - Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomasJ H Lee
Departments of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Int J Radiat Oncol Biol Phys 47:945-53. 2000..To determine the clinical outcomes and potential impact of adjuvant chemoradiation in patients undergoing surgical resection of ampullary carcinoma... - COX-2 inhibitors in oncologyDaniel G Haller
University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Semin Oncol 30:2-8. 2003 - Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancerKeith T Flaherty
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Cancer 97:1985-90. 2003..The authors performed a dose escalation study of cisplatin and the novel deoxycytidine analog, tezacitabine, to determine the maximum tolerated dose of the combination... - Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089T E Le Voyer
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 21:2912-9. 2003..CONCLUSION: The number of lymph nodes analyzed for staging colon cancers is, itself, a prognostic variable on outcome. The impact of this variable is such that it may be an important variable to include in evaluating future trials... - Future directions in the treatment of pancreatic cancerDaniel G Haller
University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Semin Oncol 29:31-9. 2002..Combined-modality approaches with gemcitabine and radiation are also under active investigation... - Chemotherapy for colorectal cancerWeijing Sun
Hematology Oncology Division, Univeristy of Pennsylvania Medical Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
Hematol Oncol Clin North Am 16:969-94. 2002..Future clinical trials should be focused on optimizing and individualizing therapy for patients based on their molecular profiles to achieve maximal clinical benefit... - Recent advances in the treatment of gastric cancerW Sun
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
Drugs 61:1545-51. 2001..Although many chemotherapy regimens have been developed recently, only modest clinical efficacy has been demonstrated for advanced metastatic disease. So far, there is no single regimen considered to be standard... - Metastatic PEComa arising from renal angiomyolipoma: MRI findingsAmr K El Jack
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
J Magn Reson Imaging 26:159-61. 2007..Both benign and malignant PEComas have been reported in diverse anatomic locations. We report the MRI features of a metastatic PEComa to the liver that originated within a renal angiomyolipoma (AML)... - Long term survival after pancreatic resection for pancreatic adenocarcinomaN A Ahmad
Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
Am J Gastroenterol 96:2609-15. 2001.... - Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patientsHans Joachim Schmoll
Martin Luther University, Halle, Germany
J Clin Oncol 25:102-9. 2007..To report the results of a planned safety analysis from a phase III trial comparing capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil/leucovorin (FU/LV) as adjuvant therapy for stage III colon cancer... - Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancerA David McCollum
A D McCollum, R J Mayer, C S Fuchs, Dana Farber Cancer Institute, Boston, MA, USA
J Natl Cancer Inst 94:1160-7. 2002..In this study, we examined survival and toxic effects among African-American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer... - Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II studyHeinz Joseph Lenz
Department of Medical Oncology, University of Southern California, Los Angeles, California, USA
Cancer 109:33-40. 2007.... - Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297Jordan D Berlin
Vanderbilt University, 777 Preston Research Building, Nashville, TN 37232 6307, USA
J Clin Oncol 20:3270-5. 2002.... - Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data setMICHAEL J O'CONNELL
National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, PA 15212 5234, USA
J Clin Oncol 26:2336-41. 2008.... - Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancerDavid P Kelsen
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:3719-25. 2007..The relationship between resection type and between tumor response and outcome were also analyzed... - End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT GroupDaniel J Sargent
Department of Health Sciences Research, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 25:4569-74. 2007..We previously validated disease-free survival (DFS) after 3-year follow-up as an excellent predictor of 5-year OS results. Here we explore shorter term DFS and OS end points, as well as stage dependency... - Docetaxel in advanced gastric cancerDaniel G Haller
University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Anticancer Drugs 13:451-60. 2002..Several phase III trials are now ongoing, including a large-scale trial of docetaxel-cisplatin-5-FU versus cisplatin-5-FU. Results will show whether docetaxel improves overall response and survival, as suggested in the phase II setting... - A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancerStephen M Hahn
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
Clin Cancer Res 8:1065-72. 2002..The objective of this Phase I trial was to determine the maximally tolerated dose of the FTI L-778,123 in combination with radiotherapy in non-small cell lung cancer (NSCLC) and head and neck cancer (HNC)... - Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297David I Rosenthal
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Int J Radiat Oncol Biol Phys 72:108-13. 2008..We performed a Phase I trial to test the safety and preliminary efficacy of adding oxaliplatin to standard preoperative chemoradiation therapy for rectal cancer... - Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapyLeonard B Saltz
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 25:4793-9. 2007..We assessed the safety and efficacy of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy... - Improving resectability of hepatic colorectal metastases: expert consensus statement by Abdalla et alReid B Adams
Ann Surg Oncol 13:1281-3. 2006 - Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144Stephen R Smalley
Kansas City Community Clinical Oncology Program (CCOP, Kansas City, KS, USA
J Clin Oncol 24:3542-7. 2006..LRF with postoperative therapy is low, justifying initial resection for T1-2, N0-2 and T3, and N0-2 anterior resection candidates... - Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancerHoward S Hochster
Department of Medicine/Clinical Pharmacology, New York University Cancer Institute, New York, New York, USA
Cancer 107:676-85. 2006..Other targeted therapies also are considered for future clinical trials. Based on a comprehensive review of past trials, a consensus on endpoints in the treatment of pancreatic cancer and an approach to new trials is presented... - Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology GroupMary Armanios
Johns Hopkins University, Baltimore, MD 21205, USA
J Clin Oncol 22:4495-9. 2004..To evaluate the effect of postoperative paclitaxel and cisplatin on 2-year survival in patients with completely resected adenocarcinoma of the distal esophagus, gastro-esophageal (GE) junction, and cardia... - Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinomaJeffrey A Meyerhardt
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 98:484-95. 2003..Obesity is a risk factor for the development of colon carcinoma. The influence of body mass index (BMI) on long-term outcomes and treatment-related toxicity in patients with colon carcinoma has not been well characterized... - Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancerRamesh K Ramanathan
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
J Clin Oncol 21:2904-11. 2003.... - American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancerAl B Benson
American Society of Clinical Oncology, Alexandria, VA 22314, USA
J Clin Oncol 22:3408-19. 2004.... - Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285)Kishan J Pandya
University of Rochester Cancer Center, Rochester, NY 14642, USA
Oncology 66:118-25. 2004..To compare the efficacy and the toxicity of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer. Patients and.. - Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?Sharlene Gill
Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Clin Oncol 22:1797-806. 2004.... - Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson
Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
J Clin Oncol 22:1785-96. 2004..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies... - New perspectives in the management of pancreas cancerDaniel G Haller
Department of Medicine, The Abramson Cancer Center at the University of Pennsylvania, Philadelphia 19104-4283, USA
Semin Oncol 30:3-10. 2003..This applies not only to individual patients but also to large-scale clinical trials... - Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg
Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
J Clin Oncol 21:2059-69. 2003..In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)... - Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrenceJeffrey A Meyerhardt
Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Ann Intern Med 139:649-57. 2003.... - Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinomaJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 24:663-7. 2006..We conducted a phase II multi-institutional trial, in the West, in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate activity and safety of this combination... - Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson
Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
Int J Radiat Oncol Biol Phys 54:386-96. 2002..For future trial design, it may be preferable to perform separate studies, or a planned statistical analysis, for the "intermediate-risk" vs. the "moderately high" or "high-risk" subsets of patients... - Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent
North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 23:8664-70. 2005..A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice... - Impact of diabetes mellitus on outcomes in patients with colon cancerJeffrey A Meyerhardt
Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 21:433-40. 2003..To determine the influence of diabetes mellitus on long-term outcomes and treatment-related toxicity among patients with curatively resected colon cancer... - A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282Steven J Cohen
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497
Int J Radiat Oncol Biol Phys 62:1345-50. 2005..This randomized study was undertaken to determine whether the addition of 5-fluorouracil (5-FU) and mitomycin-C (MMC) to radiation therapy improves outcome in this patient population. Patients and.. - Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089Robert J Green
The Helen and Harry Gray Cancer Institute, 1309 North Flagler Drive, West Palm Beach, FL 33401, USA
Ann Intern Med 136:261-9. 2002..6 (CI, 1.2 to 2.2) and 6.8 (CI, 2.7 to 22.0), respectively. CONCLUSION: The incidence of second primary colorectal cancer remains high despite intensive surveillance strategies... - Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagusMohan Suntharalingam
Department of Radiation Oncology, University of Maryland School of Medicine, 22 S Greene St, Baltimore, MD 21230 e mail
J Clin Oncol 23:2325-31. 2005..A Patterns of Care Study of patients treated from 1996 to 1999 evaluated the national practice for patients receiving radiation therapy for carcinoma of the esophagus in the United States... - Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancerElizabeth A Poplin
Operations Office, 14980 Omicron Dr, San Antonio, TX 78245 3217, USA
J Clin Oncol 23:1819-25. 2005.... - The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care StudyMohan Suntharalingam
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Int J Radiat Oncol Biol Phys 56:981-7. 2003..This study examined the evaluation and treatment schemes used during this time and compared these results to the PCS data obtained between 1992 and 1994 to identify any fundamental changes in national practice... - JCO and the Public TrustDaniel G Haller
J Clin Oncol 24:323-4. 2006 - New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica ConferenceLee S Rosen
Premiere Oncology, Santa Monica, CA 90404, USA
Clin Cancer Res 13:6853s-6s. 2007....